{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:13:37Z","timestamp":1792113217189,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jaad.2020.12.026","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T16:13:34Z","timestamp":1608653614000},"page":"597-604","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches"],"prefix":"10.1016","volume":"84","author":[{"given":"David M.","family":"Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Durgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Wysocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain H.","family":"Rook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2020.12.026_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1067\/mjd.2001.116345","article-title":"Complete molecular remission during biologic response modifier therapy for S\u00e9zary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity","volume":"45","author":"Yoo","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1056\/NEJM198710083171506","article-title":"Lymphokines","volume":"317","author":"Dinarello","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.12.026_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mjd.2001.109853","article-title":"Increased interleukin 5 production in eosinophilic S\u00e9zary syndrome: regulation by interferon alfa and interleukin 12","volume":"44","author":"Suchin","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib4","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S0190-9622(96)90119-X","article-title":"Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution","volume":"35","author":"Gottlieb","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0889-8588(18)30054-6","article-title":"The immunopathogenesis of cutaneous T-cell lymphoma","volume":"9","author":"Rook","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2020.12.026_bib6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1200\/JCO.1995.13.1.257","article-title":"Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the S\u00e9zary syndrome","volume":"13","author":"Kuzel","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib7","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1984.2.4.336","article-title":"Interferons in the treatment of human cancer","volume":"2","author":"Kirkwood","year":"1984","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib8","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0889-8588(18)30060-1","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"9","author":"Olsen","year":"1995","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.jaad.2020.12.026_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/BF02505252","article-title":"Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA","volume":"288","author":"Rajan","year":"1996","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2020.12.026_bib10","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V91.2.570","article-title":"Interferon-\u03b1 resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression","volume":"91","author":"Sun","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib11","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2010.08.037","article-title":"S\u00e9zary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States cutaneous lymphoma consortium (USCLC)","volume":"64","author":"Olsen","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib12","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2141.1991.tb08119.x","article-title":"Is interferon alpha in cutaneous T-cell lymphoma a treatment of choice?","volume":"79","author":"Papa","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaad.2020.12.026_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0190-9622(89)70049-9","article-title":"Interferon alfa-2a in the treatment of cutaneous T cell lymphoma","volume":"20","author":"Olsen","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2020.12.026_bib15","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood-2011-01-325266","article-title":"Autoimmunity associated with immunotherapy of cancer","volume":"118","author":"Amos","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib16","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1536\/ihj.37.905","article-title":"Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C","volume":"37","author":"Teragawa","year":"1996","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.jaad.2020.12.026_bib17","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-12-3488","article-title":"TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma","volume":"19","author":"Guenova","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jaad.2020.12.026_bib18","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/1346-8138.12341","article-title":"Phase II study of IV interferon-gamma in Japanese patients with mycosis fungoides","volume":"41","author":"Sugaya","year":"2014","journal-title":"J Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM198702053160603","article-title":"Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy","volume":"316","author":"Edelson","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2020.12.026_bib20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.3389\/fmed.2018.00236","article-title":"Extracorporeal photopheresis\u2014an overview","volume":"5","author":"Cho","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jaad.2020.12.026_bib21","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1600-0781.2012.00689.x","article-title":"Long-term follow-up and survival of cutaneous T-cell lymphoma patients treated with extracorporeal photopheresis","volume":"28","author":"Knobler","year":"2012","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jaad.2020.12.026_bib22","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1182\/blood-2002-01-0231","article-title":"S\u00e9zary syndrome patients demonstrate a defect in dendritic cell populations: effects of CD40 ligand and treatment with GM-CSF on dendritic cell numbers and the production of cytokines","volume":"100","author":"Wysocka","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib23","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.immuni.2004.09.009","article-title":"Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells","volume":"21","author":"Kim","year":"2004","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2020.12.026_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/labmed\/lmy034","article-title":"Iron deficiency anemia in patients undergoing extracorporeal photopheresis for cutaneous T-cell lymphoma","volume":"50","author":"Sanford","year":"2019","journal-title":"Lab Med"},{"key":"10.1016\/j.jaad.2020.12.026_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/jca.21744","article-title":"Iron deficiency anemia associated with extracorporeal photopheresis: a retrospective analysis","volume":"34","author":"Kuhn","year":"2019","journal-title":"J Clin Apher"},{"key":"10.1016\/j.jaad.2020.12.026_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/archderm.141.3.315","article-title":"Biological effects of bexarotene in cutaneous T-cell lymphoma","volume":"141","author":"Budgin","year":"2005","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib27","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ajh.20952","article-title":"Bexarotene blunts malignant T-cell chemotaxis in S\u00e9zary syndrome: reduction of chemokine receptor 4-positive lymphocytes and decreased chemotaxis to thymus and activation-regulated chemokine","volume":"82","author":"Richardson","year":"2007","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2020.12.026_bib28","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2008-03-141424","article-title":"Clinical and in\u00a0vitro resistance to bexarotene in adult T-cell leukemia: loss of RXR-\u03b1 receptor","volume":"112","author":"Lin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib29","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2133.2006.07329.x","article-title":"Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion","volume":"155","author":"Assaf","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib31","doi-asserted-by":"crossref","first-page":"adv00187","DOI":"10.2340\/00015555-3443","article-title":"Pilot study of a novel therapeutic approach for refractory advanced stage folliculotropic mycosis fungoides","volume":"100","author":"Del Guzzo","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2020.12.026_bib32","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4049\/jimmunol.154.3.1491","article-title":"IL-12 reverses cytokine and immune abnormalities in S\u00e9zary syndrome","volume":"154","author":"Rook","year":"1995","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2020.12.026_bib33","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood.V94.3.902.415k23_902_908","article-title":"Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses","volume":"94","author":"Rook","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib34","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.4049\/jimmunol.163.7.4073","article-title":"Depressed IL-12-mediated signal transduction in T cells from patients with S\u00e9zary syndrome is associated with the absence of IL-12 receptor \u03b22 mRNA and highly reduced levels of STAT4","volume":"163","author":"Showe","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2020.12.026_bib35","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaad.2006.06.038","article-title":"A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides","volume":"55","author":"Duvic","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib36","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1182\/blood.V128.22.4165.4165","article-title":"A single-arm PHASE 2A study of NM-IL-12 (rHu-IL12) in patients with mycosis fungoides-type CTCL (MF) undergoing low-dose total skin electron beam therapy (LD-TSEBT)","volume":"128","author":"Kim","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib37","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1001\/archderm.138.9.1137","article-title":"Treatment of stage IA cutaneous T-cell lymphoma with topical application of the immune response modifier imiquimod","volume":"138","author":"Suchin","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib38","doi-asserted-by":"crossref","first-page":"119","DOI":"10.4103\/0019-5154.174085","article-title":"New treatment options for mycosis fungoides","volume":"61","author":"Shipman","year":"2016","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib39","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1182\/blood-2015-02-630335","article-title":"Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma","volume":"126","author":"Rook","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib40","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib41","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jdcr.2015.08.007","article-title":"Clearance of folliculotropic and tumor mycosis fungoides with topical 5% imiquimod","volume":"1","author":"Gordon","year":"2015","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.jaad.2020.12.026_bib42","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/09546634.2017.1294728","article-title":"Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series","volume":"28","author":"Lewis","year":"2017","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2020.12.026_bib43","doi-asserted-by":"crossref","first-page":"e1011524","DOI":"10.1080\/2162402X.2015.1011524","article-title":"Depletion of regulatory T cells by targeting CC chemokine receptor type 4 with mogamulizumab","volume":"4","author":"Ni","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.jaad.2020.12.026_bib44","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib45","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1001\/archdermatol.2010.200","article-title":"Increased programmed death-1 expression on CD4+ T cells in cutaneous T-cell lymphoma: implications for immune suppression","volume":"146","author":"Samimi","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2020.12.026_bib46","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1200\/JCO.19.01056","article-title":"Pembrolizumab in relapsed and refractory mycosis fungoides and S\u00e9zary syndrome: a multicenter phase II study","volume":"38","author":"Khodadoust","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib47","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib48","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00277-017-2929-6","article-title":"Successful treatment of refractory S\u00e9zary syndrome by anti-PD-1 antibody (nivolumab)","volume":"96","author":"Shen","year":"2017","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaad.2020.12.026_bib49","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/bloodadvances.2018030577","article-title":"Targeting CD47 in S\u00e9zary syndrome with SIRP\u03b1Fc","volume":"3","author":"Johnson","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2020.12.026_bib50","first-page":"4076","volume":"130","author":"Querfeld","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2020.12.026_bib51","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/S0959-8049(19)30600-8","article-title":"Anti-CD7 immunotherapy is mediated by cytotoxic CD107a+ IFN-\u03b3\u2013NK cells and can be potentiated by interferon-\u03b1 in cutaneous lymphoma","volume":"119","author":"Kruglov","year":"2019","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.jaad.2020.12.026_bib52","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood.V128.22.221.221","article-title":"Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed\/refractory acute lymphoblastic leukemia (ALL)","volume":"128","author":"Grupp","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2020.12.026_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in\u00a0vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaad.2020.12.026_bib55","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11899-020-00590-5","article-title":"Hematopoietic cell transplantation and adoptive cell therapy in peripheral T cell lymphoma","volume":"15","author":"Rogers","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.jaad.2020.12.026_bib56","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3389\/fonc.2019.00126","article-title":"Chimeric antigen receptors for T-cell malignancies","volume":"9","author":"Scherer","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.jaad.2020.12.026_bib57","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","article-title":"Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell","volume":"24","author":"Ruella","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2020.12.026_bib58","doi-asserted-by":"crossref","first-page":"e99442","DOI":"10.1172\/jci.insight.99442","article-title":"TCR\u03b1\u03b2\/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy","volume":"3","author":"Rasaiyaah","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2020.12.026_bib59","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1038\/s41375-018-0065-5","article-title":"An \u201coff-the-shelf\u201d fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies","volume":"32","author":"Cooper","year":"2018","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.jaad.2020.12.026_bib60","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1016\/S1525-0016(16)34020-5","article-title":"CD5 CAR for the treatment of T-cell malignancies","volume":"23","author":"Mamonkin","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.jaad.2020.12.026_bib61","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/ajh.24794","article-title":"Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies","volume":"92","author":"Perera","year":"2017","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaad.2020.12.026_bib62","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/leu.2015.311","article-title":"Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells","volume":"30","author":"Pinz","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.jaad.2020.12.026_bib63","article-title":"Low-dose total skin electron beam therapy as part of a multimodality regimen for S\u00e9zary syndrome: clinical, immunologic and molecular analysis","author":"Durgin","year":"2020","journal-title":"JAMA Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220331868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962220331868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:58:08Z","timestamp":1759273088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962220331868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0190962220331868"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2020.12.026","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2020.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/S0190-9622(21)00117-1","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}